Lantern Pharma Inc. · NASDAQ:LTRN
BIOS Capital Management, LP reported a 8.58% stake in Lantern Pharma Inc. (Schedule 13D/A)
Event Feb 20, 2026 · Filed Feb 23, 2026
BIOS Capital Management, LP reported a 8.58% stake in Lantern Pharma Inc., 960,026 shares, with active intent on Feb 20, 2026. Filed Feb 23, 2026 (Schedule 13D/A).
- Stake
- 8.58%
- Shares
- 960,026
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 14 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Bios Fund I, LP | 2.57% | 287,619 |
| BIOS EQUITY PARTNERS II, LP | 4.27% | 478,079 |
| BIOS FUND I QP, LP | 1.50% | 168,235 |
| BIOS FUND II, LP | 0.91% | 101,665 |
| BIOS FUND II QP, LP | 2.97% | 331,974 |
| BIOS FUND II NT, LP | 0.40% | 44,440 |
| BP DIRECTORS, LP | 0.23% | 26,093 |
| BIOS EQUITY PARTNERS, LP | 4.31% | 481,947 |
| BIOS CAPITAL MANAGEMENT, LP | 8.58% | 960,026 |
| BIOS ADVISORS GP, LLC | 8.58% | 960,026 |
| CAVU MANAGEMENT, LP | 8.58% | 960,026 |
| CAVU ADVISORS, LLC | 8.58% | 960,026 |
| LESLIE W. KREIS | 8.58% | 960,026 |
| AARON G.L. FLETCHER | 8.58% | 960,026 |
Source
Related
- Lantern Pharma Inc.
- BIOS Capital Management, LP
- Lantern Pharma Inc. shareholders
- Schedule 13G/A · Empery Asset Management, LP · Oct 13, 2026
- Schedule 13G · Empery Asset Management, LP · Aug 4, 2026
- Schedule 13G/A · Thomas A. Satterfield, Jr. · Jul 23, 2026
- Schedule 13D/A · BIOS Advisors GP, LLC · May 15, 2026
- Form 4 · Schalop Lee Troy · May 14, 2026